Intratumoral Expression of a Composite B Cell / CD8 T Cell Biomarker Stratifies Overall Survival by Circulating Tumor DNA Status and Benefit From Adjuvant Immunotherapy in High-Risk Muscle-Invasive Urothelial Carcinoma
While tumor B8T Hi/Hi was prognostic regardless of ctDNA status, B8T Hi/Lo was predictive for atezolizumab benefit independent of ctDNA status. Thus, the B8T identified patients with ctDNA(-) status who benefited, and patients who were ctDNA(+) who did not benefit, from adjuvant atezolizumab.
Authors
- Noah M. Hahn (ORCID: https://orcid.org/0000-0002-1016-9024)
- Jean Hoffman‐Censits (ORCID: https://orcid.org/0000-0002-6970-6509)
- Burles A. Johnson (ORCID: https://orcid.org/0000-0002-7180-8790)
- David J. McConkey (ORCID: https://orcid.org/0000-0003-1971-0638)
- Adam K. Aragaki (ORCID: https://orcid.org/0000-0002-9458-0426)
- Roy Elias (ORCID: https://orcid.org/0000-0002-8555-4322)
Institutions
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
- Sidney Kimmel Comprehensive Cancer Center (US)
Publication Details
- Journal
- The Journal of Urology
- Published
- 2025-10-27
- DOI
- https://doi.org/10.1097/ju.0000000000004828
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00